Capturem Protein A Miniprep columns provide rapid, high-quality, small-scale purification and screening of monoclonal and polyclonal antibodies. These miniprep columns combine the specific antibody-binding properties of Protein A with novel Capturem technology to provide high-capacity, membrane-based affinity purification. These columns are convenient, powerful, and efficient tools for small-scale antibody purification, and offer the following advantages:
- Fast and convenient: purify antibodies in 5 minutes at room temperature
- High quality: short residence times reduce the possibility of aggregation or loss of activity
- High purity: small column bed volumes trap fewer contaminants and allow large-volume washes
- Flexible: purify a wide range of antibodies
Protein A is a cell wall protein from the bacterium Staphylococcus aureus with a high affinity for the FC region of monoclonal and polyclonal IgG-type antibodies from several different species, e.g., mouse, rat, and human antibodies. Capturem kits use a novel high-capacity membrane-based affinity technology that has previously been used to purify highly concentrated his-tagged proteins in just minutes at room temperature, via miniprep columns, maxiprep columns, or 96-well plates.
Capturem Protein A Miniprep Columns
Capturem Protein A Miniprep consists of single-use, disposable spin columns that yield up to 300 µg of purified antibody per column, depending upon species and antibody isotype. These miniprep columns are suitable for purification of antibodies from animal sera, ascites fluid, cell culture media, and other sources. Capturem Protein A Miniprep columns can purify antibodies with a 5-minute protocol at room temperature, and at a binding capacity of up to 75 mg/ml or more, far exceeding the capacity of resin-bound Protein A columns.
Where resin columns fall short, Capturem Protein A Minipreps yield highly pure monoclonal and polyclonal antibodies in just 5 minutes, from loading the sample through elution. Short residence times greatly reduce the possibility of protein aggregation or loss of activity, giving downstream applications a higher probability of success.